UroGen Pharma (URGN) Total Current Liabilities (2016 - 2026)
UroGen Pharma's (URGN) quarterly Total Current Liabilities came in at $50.6 million in Q1 2026, up 20.56% YoY from $42.0 million in Q1 2025, and up 9.08% on a QoQ basis from $46.4 million in Q4 2025.
UroGen Pharma (URGN) Total Current Liabilities (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Total Current Liabilities data on file, last reported at $50.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 20.56% year-over-year to $50.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.6 million (up 20.56% YoY) and the FY2025 annual result came in at $46.4 million, up 1.02% from the prior year.
- Total Current Liabilities rose to $50.6 million in Q1 2026, from $46.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $50.6 million in Q1 2026 to a low of $18.0 million in Q2 2022.
- A 5-year average of $32.8 million and a median of $31.2 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities fell 5.33% — and 2025, when it jumped 59.45%.
- Tracing URGN's Total Current Liabilities over 5 years: stood at $23.9 million in 2022, then jumped by 30.51% to $31.2 million in 2023, then surged by 47.22% to $45.9 million in 2024, then advanced by 1.02% to $46.4 million in 2025, then rose by 9.08% to $50.6 million in 2026.
- The last three Total Current Liabilities figures came in at $50.6 million (Q1 2026), $46.4 million (Q4 2025), and $42.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 61.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.92 Mn |
| Mar 31, 2026 | 50.64 Mn |
| Dec 31, 2025 | 46.42 Mn |
| Sep 30, 2025 | 42.24 Mn |
| Jun 30, 2025 | 47.55 Mn |
| Mar 31, 2025 | 42.00 Mn |
| Dec 31, 2024 | 45.95 Mn |
| Sep 30, 2024 | 32.79 Mn |
| Jun 30, 2024 | 34.22 Mn |
| Mar 31, 2024 | 26.34 Mn |
| Dec 31, 2023 | 31.21 Mn |
| Sep 30, 2023 | 25.79 Mn |
| Jun 30, 2023 | 26.77 Mn |
| Mar 31, 2023 | 25.23 Mn |
| Dec 31, 2022 | 23.92 Mn |
| Sep 30, 2022 | 19.00 Mn |
| Jun 30, 2022 | 18.04 Mn |
| Mar 31, 2022 | 19.09 Mn |
| Dec 31, 2021 | 22.38 Mn |
| Sep 30, 2021 | 19.81 Mn |